NewAmsterdam Pharma Company N.V. (NAMS) Operating Margin
- Operating margin · 12 months: Value -3432.20%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -3432.20% | Operating income / revenue. Period ending 2026-06-30. $-244.41M ÷ $7.12M × 100 ≈ -3432.20% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -244.41M USD | Operating Income (Loss) |
| Revenue | 7.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 149.25M USD | Research and Development Expense |
| Selling, general and administration | 102.28M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-244.41M | $7.12M | (m) | $149.25M | $102.28M | -3432.20% |
| 2026-03-31 | $-215.18M | $22.57M | (m) | $135.09M | $102.65M | -953.59% |
| 2025-12-31 | $-225.68M | $22.50M | (m) | $141.83M | $106.35M | -1002.90% |
| 2025-09-30 | $-202.93M | $35.24M | (m) | $138.13M | $100.04M | -575.81% |
| 2025-06-30 | $-172.79M | $64.01M | (m) | $142.86M | $93.93M | -269.96% |
| 2025-03-31 | $-189.73M | $47.14M | (m) | $153.73M | $83.14M | -402.49% |
| 2024-12-31 | $-176.29M | $45.56M | (m) | $151.41M | $70.45M | -386.91% |
| 2024-09-30 | $-184.13M | $33.59M | (m) | $157.80M | $59.92M | -548.12% |
| 2024-06-30 | $-208.69M | $7.42M | (m) | $165.47M | $50.64M | -2811.00% |
| 2024-03-31 | $-198.60M | $6.86M | (m) | $161.43M | $44.02M | -2894.14% |
| 2023-12-31 | $-182.97M | $14.09M | (m) | $159.42M | $37.63M | -1298.56% |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-3.56M | $102.69M | (m) | $86.74M | $19.51M | -3.46% |
| 2021-12-31 | $-34.98M | (m) | (m) | $28.97M | $6.00M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |